Ascentage Pharma arrives at the close of fiscal 2025 as a commercial-stage biopharma caught between two opposing signals. Its two approved drugs - Olverembatinib and Lisaftoclax - are selling more than ever inside China, nearly doubling product revenue in a single year. Yet the headline financial statement shows total revenue falling 41.5% in U.S. dollars, the company's annual net loss more than tripling, and a stock that has been cut roughly 60% from its 52-week high. The split is not a contradiction; it is the whole point of the report.
The revenue decline was arithmetic, not decay. In 2024 Ascentage took a one-time intellectual-property payment under its 2024 option agreement with Takeda - roughly $97 million - that had no 2025 counterpart. Strip that non-repeating item and the story inverts: pharmaceutical product sales rose about 91% to US$71.4 million (RMB499.3 million), commercialization-rights income grew, and the company closed the year with more customers buying two newly reimbursed medicines. The loss widened to US$177.7 million (RMB1,243.0 million) primarily because Ascentage spent more - research and development expense rose one-fifth - on a pipeline the market now must price as a global option, not a China story.
The second signal is the overhang. In July 2026, with roughly twelve months of cash on hand, Ascentage registered an at-the-market program of up to US$200 million and a shelf covering as many as 125 million ADSs - against roughly 93 million ADS-equivalents outstanding. The market marked the equity down sharply on the financing news, and at US$18.98 the ADS now trades near the bottom of its US$16.36–US$48.45 range. The investment question is whether the underlying engine - two approved drugs growing fast inside China, nine U.S.- and/or international registrational trials (four of them FDA-cleared) - can grow into an equity that the financing overhang has repriced first.